# Prevention of Recurrence of Diverticulitis

> **NCT00545103** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 592 (actual)

## Conditions studied

- Diverticulitis

## Interventions

- **DRUG:** SPD476, MMX™ mesalazine, 1.2g extended release tablet
- **DRUG:** SPD476, MMX™ mesalazine, 2.4g extended release tablet
- **DRUG:** SPD476, MMX™ mesalazine, 4.8g extended release tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00545103
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-06
- **Primary completion:** 2011-11-28
- **Final completion:** 2011-11-28
- **Target enrollment:** 592 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545103, "Prevention of Recurrence of Diverticulitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00545103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*